French bill tightens up on safety and conflicts of interest, but not drug approval criteria
This article was originally published in Scrip
Executive Summary
Longer waits before starting promotional campaigns, higher costs associated with new product approvals, and a sharp fall in sales rep employment levels: All are in prospect for the pharmaceutical industry if the new French bill on regulatory reform is passed in its present form.